Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics Inc (NQ: TVTX )

7.850 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 868
Open 7.850
Bid (Size) 7.540 (10)
Ask (Size) 7.850 (10)
Prev. Close 7.850
Today's Range 7.850 - 7.850
52wk Range 7.000 - 26.55
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
Via Benzinga
Expert Ratings for Travere Therapeutics
Via Benzinga

Performance

YTD
-62.00%
-62.00%
1 Month
-39.43%
-39.43%
3 Month
-50.85%
-50.85%
6 Month
-63.72%
-63.72%
1 Year
-67.45%
-67.45%

More News

Read More
Micron Technology To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Analyst Ratings for Travere Therapeutics
Via Benzinga
The Latest Analyst Ratings for Travere Therapeutics
Via Benzinga
Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challenges
Via Benzinga
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Shares of Travere Therapeutics Are Slumping Thursday
Via The Motley Fool
Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low
Via Investor's Business Daily
Exposures Product Safety
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
From Travere Therapeutics, Inc.
Via GlobeNewswire
Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
Via Benzinga
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.